Akeso at ASCO 2026: China Biotech’s Coming of Age as Ivonescimab Beats Keytruda
Akeso’s Ivonescimab Data at ASCO 2026 Signals China’s Transition from Generic Drugs to Frontier Oncology Innovation China’s biotech sector has evolved from generic drug manufacturing to cutting-edge oncology research, with…
-
China Pharma R&D Surge: Hengrui and Qilu Lead Innovative Drug Push
What Happened China’s pharmaceutical industry is experiencing an unprecedented surge in research and development activity in 2026, led by Hengrui Medicine (600276.SS) and Qilu Pharmaceutical, the country’s two most R&D-intensive…
